Skip to main content
SLU publication database (SLUpub)

Research article2019Peer reviewedOpen access

Experimental Autoimmune Encephalomyelitis Potentiates Mouse Mast Cell Protease 4-Dependent Pressor Responses to Centrally or Systemically Administered Big Endothelin-1

Desbiens, Louisane; Lapointe, Catherine; Gendron, Louis; Gharagozloo, Marjan; Vincent, Laurence; Pejler, Gunnar; Gris, Denis; D'Orleans-Juste, Pedro

Abstract

Multiple sclerosis is a neurodegenerative disease affecting predominantly female patients between 20 and 45 years of age. We previously reported the significant contribution of mouse mast cell protease 4 (mMCP-4) in the synthesis of endothelin-1 (ET-1) in healthy mice and in a murine model of experimental autoimmune encephalomyelitis (EAE). In the current study, the cardiovascular effects of ET-1 and big endothelin-1 (big-ET-1) administered systemically or intrathecally were assessed in the early preclinical phase of EAE in telemetry instrumented/conscious mice. Chymase-specific enzymatic activity was also measured in the lung, brain, and mast cell extracts in vitro. Finally, the impact of EAE immunization was studied on the pulmonary and brain mRNA expression of different genes of the endothelin pathway, interleukin-33 (IL-33), and monitoring of immunoreactive tumor necrosis factor-alpha (TNF-alpha). Systemically or intrathecally administered big-ET-1 triggered increases in blood pressure in conscious mice. One week post-EAE, the pressor responses to big-ET-1 were potentiated in wild-type (WT) mice but not in mMCP-4 knockout (KO) mice. EAE triggered mMCP-4-specific activity in cerebral homogenates and peritoneal mast cells. Enhanced pulmonary, but not cerebral preproendothelin-1 and IL-33 mRNA were found in KO mice and further increased 1 week post-EAE immunization, but not in WT animals. Finally, TNF-alpha levels were also increased in serum from mMCP-4 KO mice, but not WT, 1 week post-EAE. Our study suggests that mMCP-4 activity is enhanced both centrally and systemically in a mouse model of EAE.

Published in

Journal of Pharmacology and Experimental Therapeutics
2019, Volume: 370, number: 3, pages: 437-446 Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS

    UKÄ Subject classification

    Pharmacology and Toxicology

    Publication identifier

    DOI: https://doi.org/10.1124/jpet.118.256016

    Permanent link to this page (URI)

    https://res.slu.se/id/publ/101981